Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma

IF 20.1 1区 医学 Q1 ONCOLOGY
Kai Huang
{"title":"Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma","authors":"Kai Huang","doi":"10.1002/cac2.12628","DOIUrl":null,"url":null,"abstract":"<p>The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. However, despite their revolutionary success, the use of ICIs is often complicated by immune-related adverse events (irAEs), which can range from mild symptoms to severe, life-threatening conditions. Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy [<span>1</span>].</p><p>In a recent study published in <i>Nature Cancer</i>, Dimitriou <i>et al.</i> [<span>2</span>] provide novel insights into the immunological processes driving irAEs in melanoma patients treated with ICIs. The researchers identified a significant increase in interleukin-17A (IL-17A) expressing CD4<sup>+</sup> T cells at the onset of irAEs, pointing to a type III immune response as a key factor in these adverse events. This discovery not only deepens our understanding of irAEs but also suggests a potential therapeutic target for mitigating these toxicities without compromising the antitumor efficacy of ICIs.</p><p>What sets these findings apart is their contribution to a broader understanding of the mechanisms behind ICIs’ AEs compared to primary autoimmune diseases. While irAEs share certain immune mechanisms with autoimmune diseases, such as rheumatoid arthritis or psoriasis, the immunological context of ICIs is distinct because of the pharmacological disruption of immune checkpoints [<span>3</span>]. The study highlights the difference between irAEs and primary autoimmune disease by showing that IL-17A expressing CD4<sup>+</sup> T cells are particularly implicated in ICI-induced toxicity, which is not a prominent feature of many primary autoimmune conditions.</p><p>The study utilized a comprehensive approach, including proteomic analyses, multiplex cytokine and chemokine assays, and flow cytometry, to examine the immune profiles of melanoma patients undergoing ICI therapy. A critical finding was the consistent upregulation of IL-17A, along with other type I and III cytokines, at the onset of irAEs. These results were corroborated by the observation that IL-17A expressing CD4<sup>+</sup> T cells were significantly elevated in patients experiencing irAEs compared to those who did not.</p><p>Importantly, the authors provided proof-of-principle evidence for the therapeutic potential of targeting IL-17A in managing irAEs. In a small cohort of patients with severe, corticosteroid-refractory irAEs, treatment with the anti-IL-17A monoclonal antibody secukinumab led to a resolution of symptoms. Secukinumab, primarily used in the treatment of psoriasis, where IL-17A plays a well-established pathogenic role, offers a novel therapeutic option for managing irAEs [<span>4</span>]. Its efficacy in these patients not only underscores the importance of IL-17A in both conditions but also suggests that treatment strategies from autoimmune diseases can be successfully repurposed for irAEs in cancer immunotherapy. This outcome suggests that IL-17A blockade could be a viable strategy for controlling irAEs, offering a new avenue for improving the safety profile of ICIs in melanoma treatment.</p><p>These findings are particularly relevant given the expanding use of ICIs across various cancers. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. Moreover, the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs.</p><p>The implications of this study extend beyond melanoma. The mechanisms of irAEs are likely to be similar across different cancers treated with ICIs, suggesting that these findings could have broader applicability. As such, researchers and clinicians should consider exploring the role of IL-17A and type III immune responses in other oncological contexts, with the goal of developing more effective and personalized immunotherapy strategies.</p><p>In conclusion, this study marks a significant advancement in the field of cancer immunotherapy. By identifying IL-17A expressing CD4<sup>+</sup> T cells as a central player in irAE development, the study not only enhances our understanding of these toxicities but also provides a promising new target for therapeutic intervention. As the use of ICIs continues to grow, these findings offer a path forward for improving patient outcomes by balancing the benefits of immunotherapy with the need to manage its associated risks effectively.</p><p>Kai Huang drafted and revised the manuscript.</p><p>The author declares no conflict of interest.</p><p>Not applicable.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 1","pages":"56-57"},"PeriodicalIF":20.1000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758441/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12628","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors (ICIs), particularly in the management of advanced melanoma. However, despite their revolutionary success, the use of ICIs is often complicated by immune-related adverse events (irAEs), which can range from mild symptoms to severe, life-threatening conditions. Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy [1].

In a recent study published in Nature Cancer, Dimitriou et al. [2] provide novel insights into the immunological processes driving irAEs in melanoma patients treated with ICIs. The researchers identified a significant increase in interleukin-17A (IL-17A) expressing CD4+ T cells at the onset of irAEs, pointing to a type III immune response as a key factor in these adverse events. This discovery not only deepens our understanding of irAEs but also suggests a potential therapeutic target for mitigating these toxicities without compromising the antitumor efficacy of ICIs.

What sets these findings apart is their contribution to a broader understanding of the mechanisms behind ICIs’ AEs compared to primary autoimmune diseases. While irAEs share certain immune mechanisms with autoimmune diseases, such as rheumatoid arthritis or psoriasis, the immunological context of ICIs is distinct because of the pharmacological disruption of immune checkpoints [3]. The study highlights the difference between irAEs and primary autoimmune disease by showing that IL-17A expressing CD4+ T cells are particularly implicated in ICI-induced toxicity, which is not a prominent feature of many primary autoimmune conditions.

The study utilized a comprehensive approach, including proteomic analyses, multiplex cytokine and chemokine assays, and flow cytometry, to examine the immune profiles of melanoma patients undergoing ICI therapy. A critical finding was the consistent upregulation of IL-17A, along with other type I and III cytokines, at the onset of irAEs. These results were corroborated by the observation that IL-17A expressing CD4+ T cells were significantly elevated in patients experiencing irAEs compared to those who did not.

Importantly, the authors provided proof-of-principle evidence for the therapeutic potential of targeting IL-17A in managing irAEs. In a small cohort of patients with severe, corticosteroid-refractory irAEs, treatment with the anti-IL-17A monoclonal antibody secukinumab led to a resolution of symptoms. Secukinumab, primarily used in the treatment of psoriasis, where IL-17A plays a well-established pathogenic role, offers a novel therapeutic option for managing irAEs [4]. Its efficacy in these patients not only underscores the importance of IL-17A in both conditions but also suggests that treatment strategies from autoimmune diseases can be successfully repurposed for irAEs in cancer immunotherapy. This outcome suggests that IL-17A blockade could be a viable strategy for controlling irAEs, offering a new avenue for improving the safety profile of ICIs in melanoma treatment.

These findings are particularly relevant given the expanding use of ICIs across various cancers. The ability to identify patients at risk for severe irAEs through biomarkers like IL-17A could enable more personalized treatment approaches. Moreover, the successful use of secukinumab in this context opens the door to broader clinical trials aimed at validating IL-17A as a therapeutic target, potentially leading to the development of new protocols for managing irAEs.

The implications of this study extend beyond melanoma. The mechanisms of irAEs are likely to be similar across different cancers treated with ICIs, suggesting that these findings could have broader applicability. As such, researchers and clinicians should consider exploring the role of IL-17A and type III immune responses in other oncological contexts, with the goal of developing more effective and personalized immunotherapy strategies.

In conclusion, this study marks a significant advancement in the field of cancer immunotherapy. By identifying IL-17A expressing CD4+ T cells as a central player in irAE development, the study not only enhances our understanding of these toxicities but also provides a promising new target for therapeutic intervention. As the use of ICIs continues to grow, these findings offer a path forward for improving patient outcomes by balancing the benefits of immunotherapy with the need to manage its associated risks effectively.

Kai Huang drafted and revised the manuscript.

The author declares no conflict of interest.

Not applicable.

以 IL-17A 为靶点,控制黑色素瘤免疫疗法引起的毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信